Biotech and Pharma

Novartis reaches $678 million settlement of U.S. fraud lawsuit

Key Points
  • Novartis has agreed to pay $678 million to settle a civil fraud lawsuit.
  • The U.S. government accused the Swiss drugmaker of illegally providing doctors with cash payments and other perks to induce them to prescribe its cardiovascular and diabetes drugs.
  • The DOJ announced the settlement late Wednesday to resolve charges that Novartis violated the federal False Claims Act and an anti-kickback statute.
The Novartis headquarters in Basel, Switzerland.
Arnd Wiegmann | Reuters

Novartis has agreed to pay $678 million to settle a civil fraud lawsuit in which the U.S. government accused the Swiss drugmaker of illegally providing doctors with cash payments and other perks to induce them to prescribe its cardiovascular and diabetes drugs.

The U.S. Department of Justice announced the settlement late on Wednesday to resolve charges that Novartis violated the federal False Claims Act and an anti-kickback statute.